Aph-1 Inhibitors
Aph-1 inhibitors belong to a distinct chemical class known for their significant role in molecular interactions within specific cellular pathways. These inhibitors target the Aph-1 protein, which is a crucial component of the γ-secretase enzyme complex. The γ-secretase complex plays a vital role in proteolytic processing and cleavage of various transmembrane proteins, including amyloid precursor protein (APP) and Notch receptors. By specifically inhibiting Aph-1, these compounds can modulate the activity of the γ-secretase complex, thereby affecting the cleavage and release of downstream signaling peptides. Aph-1 inhibitors are designed to bind to the active site of the Aph-1 protein, thus preventing its proper interaction with other components of the γ-secretase complex. As a result, the enzymatic activity of the complex is disrupted, leading to altered processing of its substrates.
The inhibition of Aph-1 activity has been studied for its potential impact on cellular processes, particularly in the context of the central nervous system and developmental pathways. Research on these inhibitors has shed light on their involvement in regulating Notch signaling, which plays a critical role in cell fate determination and differentiation during embryonic development. Due to their specific molecular targets and mode of action, Aph-1 inhibitors have garnered considerable interest in the scientific community. Researchers are actively exploring the potential implications of manipulating γ-secretase activity through Aph-1 inhibition in various cellular contexts. By understanding the intricate mechanisms behind Aph-1 inhibitors, scientists hope to gain further insights into cellular processes and uncover new avenues for drug development and research in the future.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Semagacestat | 425386-60-3 | sc-364614 sc-364614A | 10 mg 50 mg | $350.00 $1200.00 | 1 | |
Semagacestat, originally developed as a γ-secretase inhibitor, has a unique mechanism distinct from typical inhibitors in this class. It increases intracellular byproduct peptides and long Aβ species rather than causing a loss of function in presenilins, core proteins in the γ-secretase complex. This action classifies Semagacestat as a pseudo-inhibitor of γ-secretase, offering an alternative approach to studying γ-secretase activity and its implications in cellular processes. | ||||||
BMS-708163 | 1146699-66-2 | sc-364444 sc-364444A | 10 mg 50 mg | $480.00 $1455.00 | 1 | |
A γ-secretase inhibitor developed for selectively inhibiting amyloid precursor protein (APP) cleavage over Notch cleavage. In cell culture studies and in vivo models, it has been shown to reduce amyloid β-peptide levels in cerebrospinal fluid without causing Notch-related toxicities. This selectivity is based on its mechanism of targeting APP cleavage, a key process in Alzheimer's disease pathology, making Avagacestat a compound of interest in neuroscience and pharmacological research. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $430.00 $1389.00 | 1 | |
RO4929097 is a gamma-secretase inhibitor that selectively targets Notch signaling over amyloid precursor protein (APP) processing. It works by inhibiting the production of intracellular Notch, which leads to decreased expression of downstream Notch target genes like Hes1. This action results in changes in cell morphology and gene expression patterns, particularly impacting Notch signaling pathways. | ||||||